Starling Oncology (STLN) Earnings
Starling Oncology reported on November 5, 2026: EPS of -0.13 against -0.07 expected, a miss.
Latest results
In the quarter ended September 2026, Starling Oncology had revenue of $170M, up 24.3% on a year earlier, and diluted EPS of -0.13.
- Reported
- Nov 5, 2026after the close
- EPS reported
- -0.13-0.07 expected
- Result
- Missedby 0.06
- Revenue
- $170M+24.3% on a year earlier
Revenue and EPS by quarter
Starling Oncology revenue and EPS by quarter
12 quartersQuarterly results
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | $170M | +24.3% | -0.13 | — | -1.8% | 2026-11-06 |
| Jun 30, 2026 | $161M | +34.6% | -0.08 | — | -2.9% | 2026-08-06 |
| Mar 31, 2026 | $147M | +41.2% | -0.02 | — | -4.4% | 2026-05-07 |
| Dec 31, 2025 | $142M | +41.6% | — | — | -4.9% | 2026-03-12 |
| Sep 30, 2025 | $137M | +36.7% | -0.14 | — | -5.9% | 2025-11-13 |
| Jun 30, 2025 | $120M | +21.5% | -0.15 | — | -9.4% | 2025-08-13 |
| Mar 31, 2025 | $104M | +10.3% | -0.21 | — | -9.5% | 2025-05-14 |
| Dec 31, 2024 | $100M | +16.9% | — | — | -11.9% | 2025-03-26 |
| Sep 30, 2024 | $100M | +21.8% | -0.18 | — | -13.9% | 2024-11-13 |
| Jun 30, 2024 | $99M | +22.9% | -0.17 | — | -16.6% | 2024-08-13 |
| Mar 31, 2024 | $95M | +24.2% | -0.22 | — | -19.0% | 2024-05-14 |
| Dec 31, 2023 | $86M | +20.1% | — | — | -17.8% | 2024-03-28 |
GAAP diluted EPS as filed with the SEC; growth is against the same quarter a year earlier. The EPS compared with estimates can be on the company's adjusted basis.
Also reporting the week of November 2
Apple Inc MonAdvanced Micro Devices Inc TuePalantir Technologies Inc. MonToyota Motor Corporation ADR WedAmgen Inc TueArista Networks TueMcDonald’s Corporation WedArm Holdings plc American Depositary Shares WedEarnings calendar →
Questions about Starling Oncology
Did Starling Oncology beat earnings estimates?
In its report on November 5, 2026, Starling Oncology missed the EPS estimate: -0.13 reported against -0.07 expected.
How did Starling Oncology do last quarter?
In the quarter ended September 2026, Starling Oncology had revenue of $170M, up 24.3% on a year earlier, and diluted EPS of -0.13.
From Starling Oncology's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.